Patients with relapsed and refractory (R/R) aggressive B-cell non-Hodgkin lymphomas have historically poor survival outcomes, with chimeric antigen receptor T-cell (CAR-T) therapy now presenting a curative option for a subset of those patients. However, with the approval of several novel bispecific monoclonal antibody (BsAb) therapies with considerable activity in R/R aggressive large B-cell lymphomas (LBCL), patients and oncologists will be faced with decisions regarding how to sequence CAR-T and BsAb therapies based on patient- and disease-related factors. In this review, we compare CAR-T and BsAb therapies for R/R LBCL, highlighting data on the efficacy and toxicity of each treatment paradigm, and provide a roadmap for sequencing these highly effective therapies.

1.
Neelapu
SS
,
Jacobson
CA
,
Ghobadi
A
, et al.
5-Year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1) [published online February 23, 2023]
.
Blood
.
doi:10.1182/blood.2022018893
.
2.
Chong
EA
,
Ruella
M
,
Schuster
SJ
;
Lymphoma Program Investigators at the University of Pennsylvania
.
Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy
.
N Engl J Med
.
2021
;
384
(
7
):
673
-
674
.
doi:10.1056/NEJMc2030164
.
Google Scholar
Crossref
Search ADS
PubMed
 
3.
Jain
T
,
Olson
TS
,
Locke
FL
.
How I treat cytopenias after CAR T-cell therapy
.
Blood
.
2023
;
141
(
20
):
2460
-
2469
.
doi:10.1182/blood.2022017415
.
Google Scholar
PubMed
 
4.
Maloney
DG
,
Kuruvilla
J
,
Liu
FF
, et al.
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
.
J Hematol Oncol
.
2021
;
14
(
1
):
140
.
doi:10.1186/s13045-021-01144-9
.
Google Scholar
Crossref
Search ADS
PubMed
 
5.
Neelapu
SS
,
Locke
FL
,
Bartlett
NL
, et al.
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
.
N Engl J Med
.
2017
;
377
(
26
):
2531
-
2544
.
doi:10.1056/NEJMoa1707447
.
Google Scholar
Crossref
Search ADS
PubMed
 
6.
Schuster
SJ
,
Tam
CS
,
Borchmann
P
, et al.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
.
Lancet Oncol
.
2021
;
22
(
10
):
1403
-
1415
.
doi:10.1016/S1470-2045(21)00375-2
.
Google Scholar
Crossref
Search ADS
PubMed
 
7.
Abramson
JS
,
Palomba
ML
,
Gordon
LI
, et al.
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
.
Lancet
.
2020
;
396
(
10254
):
839
-
852
.
doi:10.1016/S0140-6736(20)31366-0
.
Google Scholar
Crossref
Search ADS
PubMed
 
8.
Dickinson
MJ
,
Carlo-Stella
C
,
Morschhauser
F
, et al.
Glofitamab for relapsed or refractory diffuse large b-cell lymphoma
.
N Engl J Med
.
2022
;
387
(
24
):
2220
-
2231
.
doi:10.1056/NEJMoa2206913
.
Google Scholar
Crossref
Search ADS
PubMed
 
9.
Hutchings
M
,
Carlo-Stella
C
,
Morschhauser
F
, et al.
Relapse is uncommon in patients with large B-cell lymphoma who are in complete remission at the end of fixed-course glofitamab treatment
.
Blood
.
2022
;
140
(
suppl 1
):
1062
-
1064
.
doi:10.1182/blood-2022-157554
.
Google Scholar
 
10.
Hutchings
M
,
Mous
R
,
Clausen
MR
, et al.
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase ½ study
.
Lancet
.
2021
;
398
(
10306
):
1157
-
1169
.
doi:10.1016/S0140-6736(21)00889-8
.
Google Scholar
Crossref
Search ADS
PubMed
 
11.
Thieblemont
C
,
Phillips
T
,
Ghesquieres
H
, et al.
Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial
.
J Clin Oncol
.
2023
;
41
(
12
):
2238
-
2247
.
doi:10.1200/JCO.22.01725
.
Google Scholar
Crossref
Search ADS
PubMed
 
12.
Budde
LE
,
Assouline
S
,
Sehn
LH
, et al.
Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study
.
J Clin Oncol
.
2022
;
40
(
5
):
481
-
491
.
doi:10.1200/JCO.21.00931
.
Google Scholar
Crossref
Search ADS
PubMed
 
13.
Bartlett
NL
,
Assouline
S
,
Giri
P
, et al.
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma [published online April 17, 2023]
.
Blood Adv
.
doi:10.1182/bloodadvances.2022009260
.
14.
Bannerji
R
,
Arnason
JE
,
Advani
RH
, et al.
Odronextamab, a human CD20 × CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
.
Lancet Haematol
.
2022
;
9
(
5
):
e327
-
e339
.
doi:10.1016/S2352-3026(22)00072-2
.
Google Scholar
Crossref
Search ADS
PubMed
 
15.
van Imhoff
GW
,
McMillan
A
,
Matasar
MJ
, et al.
Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD Study
.
J Clin Oncol
.
2017
;
35
(
5
):
544
-
551
.
doi:10.1200/JCO.2016.69.0198
.
Google Scholar
Crossref
Search ADS
PubMed
 
16.
Locke
FL
,
Miklos
DB
,
Jacobson
CA
, et al;
All ZUMA-7 Investigators and Contributing Kite Members
.
Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma
.
N Engl J Med
.
2022
;
386
(
7
):
640
-
654
.
doi:10.1056/NEJMoa2116133
.
Google Scholar
Crossref
Search ADS
PubMed
 
17.
Westin
JR
,
Locke
FL
,
Dickinson
M
, et al.
Safety and efficacy of axicabtagene ciloleucel versus standard of care in patients 65 years of age or older with relapsed/refractory large B-cell lymphoma
.
Clin Cancer Res
.
2023
;
29
(
10
):
1894
-
1905
.
doi:10.1158/1078-0432.CCR-22-3136
.
Google Scholar
Crossref
Search ADS
PubMed
 
18.
Westin
JR
,
Oluwole
OO
,
Kersten
MJ
, et al;
ZUMA-7 Investigators
;
Kite Members
.
Survival with axicabtagene ciloleucel in large B-cell lymphoma
.
N Engl J Med
.
2023
;
389
(
2
):
148
-
157
.
doi:10.1056/NEJMoa2301665
.
Google Scholar
Crossref
Search ADS
PubMed
 
19.
Abramson
JS
,
Solomon
SR
,
Arnason
J
, et al.
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
.
Blood
.
2023
;
141
(
14
):
1675
-
1684
.
doi:10.1182/blood.2022018730
.
Google Scholar
Crossref
Search ADS
PubMed
 
20.
Sehgal
A
,
Hoda
D
,
Riedell
PA
, et al.
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study
.
Lancet Oncol
.
2022
;
23
(
8
):
1066
-
1077
.
doi:10.1016/S1470-2045(22)00339-4
.
Google Scholar
Crossref
Search ADS
PubMed
 
21.
Olszewski
AJ
,
Budde
LE
,
Chavez
J
, et al.
Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged <65 and ≥65 years with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and ≥1 prior therapy: subgroup analysis of a phase Ib/II study
.
Blood
.
2022
;
140
(
suppl 1
):
3757
-
3759
.
doi:10.1182/blood-2022-159594
Google Scholar
 
22.
Patel
K
,
Riedell
PA
,
Tilly
H
, et al.
A phase 1 study of plamotamab, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed/refractory non-Hodgkin's lymphoma: recommended dose safety/efficacy update and escalation exposure-response analysis
.
Blood
.
2022
;
140
(
suppl 1
):
9470
-
9472
.
doi:10.1182/blood-2022-159586
.
Google Scholar
 
23.
Thieblemont
C
,
Clausen
MR
,
Sureda Balari
A
, et al.
Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
.
J Clin Oncol
.
2021
;
39
(
15, suppl
):
TPS7569
.
doi:10.1200/jco.2021.39.15_suppl.tps7569
.
Google Scholar
 
24.
Jacobson
CA
,
Hunter
BD
,
Redd
R
, et al.
Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity
.
J Clin Oncol
.
2020
;
38
(
27
):
3095
-
3106
.
doi:10.1200/JCO.19.02103
.
Google Scholar
Crossref
Search ADS
PubMed
 
25.
Jacobson
CA
,
Locke
FL
,
Ma
L
, et al.
Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States
.
Transplant Cell Ther
.
2022
;
28
(
9
):
581.e1
-
581.e8
.
doi:10.1016/j.jtct.2022.05.026
.
Google Scholar
Crossref
Search ADS
PubMed
 
26.
Patrick
DL
,
Powers
A
,
Jun
MP
, et al.
Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma
.
Blood Adv
.
2021
;
5
(
8
):
2245
-
2255
.
doi:10.1182/bloodadvances.2020003503
.
Google Scholar
Crossref
Search ADS
PubMed
 
27.
Johnson
PC
,
Dhawale
T
,
Newcomb
RA
, et al.
Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy
.
Blood Adv
.
2023
;
7
(
14
):
3541
-
3550
.
doi:10.1182/bloodadvances.2022009117
.
Google Scholar
Crossref
Search ADS
PubMed
 
28.
Locke
FL
,
Jacobson
C
,
Ma
L
, et al.
Real-world outcomes of axicabtagene ciloleucel (axi-cel) for the treatment of large B-cell lymphoma (LBCL): impact of age and specific organ dysfunction
.
Blood
.
2021
;
138
(
suppl 1
):
530
.
doi:10.1182/blood-2021-149679
.
Google Scholar
 
29.
Landsburg
DJ
,
Frigault
M
,
Heim
M
, et al.
Real-world outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: subgroup analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
.
Blood
.
2022
;
140
(
suppl 1
):
1584
-
1587
.
doi:10.1182/blood-2022-158822
.
Google Scholar
 
30.
Bachy
E
,
Le Gouill
S
,
Di Blasi
R
, et al.
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma
.
Nat Med
.
2022
;
28
(
10
):
2145
-
2154
.
doi:10.1038/s41591-022-01969-y
.
Google Scholar
Crossref
Search ADS
PubMed
 
31.
Chihara
D
,
Liao
L
,
Tkacz
J
, et al.
Real-world effectiveness and economic impact associated with chimeric antigen receptor T-cell therapy among older patients with relapsed/refractory diffuse large B-cell lymphoma in US
.
Blood
.
2022
;
140
(
suppl 1
):
2421
-
2423
.
doi:10.1182/blood-2022-163678
.
Google Scholar
 
32.
Nastoupil
LJ
,
Jain
MD
,
Feng
L
, et al.
Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium
.
J Clin Oncol
.
2020
;
38
(
27
):
3119
-
3128
.
doi:10.1200/JCO.19.02104
.
Google Scholar
Crossref
Search ADS
PubMed
 
33.
Sano
D
,
Lekakis
L
,
Feng
L
, et al.
Safety and efficacy of axicabtagene ciloleucel (AXI-CEL) in older patients: results from the US lymphoma CAR-T consortium
.
Hematol Oncol
.
2019
;
37
:
304
-
305
.
doi:10.1002/hon.113_2630
.
Google Scholar
Crossref
Search ADS
 
34.
Bethge
WA
,
Martus
P
,
Schmitt
M
, et al.
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany
.
Blood
.
2022
;
140
(
4
):
349
-
358
.
doi:10.1182/blood.2021015209
.
Google Scholar
PubMed
 
35.
Riedell
PA
,
Hwang
W-T
,
Nastoupil
L-J
, et al.
Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas
.
Transplant Cell Ther
.
2022
;
28
(
10
):
669
-
676
.
doi:10.1016/j.jtct.2022.07.011
.
Google Scholar
Crossref
Search ADS
PubMed
 
36.
Pasquini
MC
,
Hu
Z-H
,
Curran
K
, et al.
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
.
Blood Adv
.
2020
;
4
(
21
):
5414
-
5424
.
doi:10.1182/bloodadvances.2020003092
.
Google Scholar
Crossref
Search ADS
PubMed
 
37.
Kittai
AS
,
Huang
Y
,
Gordon
M
, et al.
Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: a multicenter analysis
.
Transplant Cell Ther
.
2021
;
27
(
1
):
46
-
52
.
doi:10.1016/j.bbmt.2020.09.028
.
Google Scholar
Crossref
Search ADS
PubMed
 
38.
Cook
MR
,
Dorris
CS
,
Makambi
KH
, et al.
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients
.
Blood Adv
.
2023
;
7
(
1
):
32
-
39
.
doi:10.1182/bloodadvances.2022008525
.
Google Scholar
Crossref
Search ADS
PubMed
 
39.
Lin
JK
,
Muffly
LS
,
Spinner
MA
,
Barnes
JI
,
Owens
DK
,
Goldhaber-Fiebert
JD
.
Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma
.
J Clin Oncol
.
2019
;
37
(
24
):
2105
-
2119
.
doi:10.1200/JCO.18.02079
.
Google Scholar
Crossref
Search ADS
PubMed
 
40.
Philipp
N
,
Kazerani
M
,
Nicholls
A
, et al.
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals
.
Blood
.
2022
;
140
(
10
):
1104
-
1118
.
doi:10.1182/blood.2022015956
.
Google Scholar
Crossref
Search ADS
PubMed
 
41.
Shouse
G
,
Danilov
AV
,
Artz
A
.
CAR T-Cell Therapy in the older person: indications and risks
.
Curr Oncol Rep
.
2022
;
24
(
9
):
1189
-
1199
.
doi:10.1007/s11912-022-01272-6
.
Google Scholar
Crossref
Search ADS
PubMed
 
42.
Greenwell
IB
,
Dahi
PB
.
Transplant and chimeric antigen receptor T-cell therapies in elderly patients with lymphoma, a narrative review
.
Ann Lymphoma
.
2022
;
6
:
8
-
8
.
doi:10.21037/aol-22-7
.
Google Scholar
Crossref
Search ADS
 
43.
Vic
S
,
Lemoine
J
,
Armand
P
,
Lemonnier
F
,
Houot
R
.
Transplant-ineligible but chimeric antigen receptor T-cells eligible: a real and relevant population
.
Eur J Cancer
.
2022
;
175
:
246
-
253
.
doi:10.1016/j.ejca.2022.08.019
.
Google Scholar
Crossref
Search ADS
PubMed
 
44.
Shouse
G
,
Kaempf
A
,
Gordon
MJ
, et al.
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma
.
Blood Adv
.
2023
;
7
(
14
):
3516
-
3529
.
doi:10.1182/bloodadvances.2022009309
.
Google Scholar
Crossref
Search ADS
PubMed
 
45.
Derman
BA
,
Kordas
K
,
Ridgeway
J
, et al.
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults
.
Blood Adv
.
2019
;
3
(
22
):
3488
-
3498
.
doi:10.1182/bloodadvances.2019000790
.
Google Scholar
Crossref
Search ADS
PubMed
 
46.
Olin
RL
,
Fretham
C
,
Pasquini
MC
, et al.
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes
.
Blood Adv
.
2020
;
4
(
12
):
2810
-
2820
.
doi:10.1182/bloodadvances.2020001719
.
Google Scholar
Crossref
Search ADS
PubMed
 
47.
Di Blasi
R
,
Le Gouill
S
,
Bachy
E
, et al.
Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis
.
Blood
.
2022
;
140
(
24
):
2584
-
2593
.
doi:10.1182/blood.2022016945
.
Google Scholar
Crossref
Search ADS
PubMed
 
48.
Gajra
A
,
Zalenski
A
,
Sannareddy
A
,
Jeune-Smith
Y
,
Kapinos
K
,
Kansagra
A
.
Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice
.
Pharmaceut Med
.
2022
;
36
(
3
):
163
-
171
.
doi:10.1007/s40290-022-00428-w
.
Google Scholar
PubMed
 
49.
Neelapu
SS
,
Jacobson
CA
,
Oluwole
OO
, et al.
Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma
.
Blood
.
2020
;
135
(
23
):
2106
-
2109
.
doi:10.1182/blood.2019004162
.
Google Scholar
Crossref
Search ADS
PubMed
 
50.
Lin
RJ
,
Lobaugh
SM
,
Pennisi
M
, et al.
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma
.
Haematologica
.
2021
;
106
(
1
):
255
-
258
.
doi:10.3324/haematol.2019.243246
.
Google Scholar
Crossref
Search ADS
PubMed
 
51.
Crochet
G
,
Audrey
C
,
Bachy
E
, et al.
CAR T-cell therapy remain effective in patients with relapse/refractory B-cell Non-Hodgkin lymphoma after bispecific antibodies exposure: results of a Lysa study based on the DESCAR-T registry
.
Blood
.
2022
;
140
(
suppl 1
):
4639
-
4641
.
doi:10.1182/blood-2022-162594
.
Google Scholar
 
52.
Hess
B
,
Li
H
,
Hossain
N
, et al.
SWOG 2114: a randomized phase II trial of consolidation therapy following CD19 CAR T-cell treatment for relapsed/refractory large B-cell or grade IIIB follicular lymphoma
.
Hematol Oncol
.
2023
;
41
(
suppl 2
):
839
-
840
.
doi:10.1002/hon.3166_ot19
.
Google Scholar
 
Copyright © 2023 by The American Society of Hematology
2023
You do not currently have access to this content.